Welcome to LookChem.com Sign In|Join Free

CAS

  • or

174266-00-3

D-Cyclobutylalanine is a non-proteinogenic amino acid, a derivative of alanine, characterized by the presence of a cyclobutane ring in its molecular structure. It is not naturally occurring in the human body and has been studied for its potential pharmaceutical applications, particularly in the development of new drugs for the treatment of neurodegenerative disorders and cancer.

174266-00-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 174266-00-3 Structure

  • Basic information

    1. Product Name: D-Cyclobutylalanine
    2. Synonyms: D-Cyclobutylalanine;D-3-Cyclobutylalanine;(R)-2-aMino-3-cyclobutylpropanoic acid;(R)-3-Cyclobutylalanine;(R)-alpha-Aminocyclobutanepropanoic acid;(Tert-Butoxy)Carbonyl (R)-3-Cyclobutylalanine
    3. CAS NO:174266-00-3
    4. Molecular Formula: C7H13NO2
    5. Molecular Weight: 143.18362
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 174266-00-3.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: 2-8°C
    8. Solubility: N/A
    9. CAS DataBase Reference: D-Cyclobutylalanine(CAS DataBase Reference)
    10. NIST Chemistry Reference: D-Cyclobutylalanine(174266-00-3)
    11. EPA Substance Registry System: D-Cyclobutylalanine(174266-00-3)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 174266-00-3(Hazardous Substances Data)

174266-00-3 Usage

Uses

Used in Pharmaceutical Industry:
D-Cyclobutylalanine is used as a potential therapeutic agent for the treatment of neurodegenerative disorders and cancer. It exhibits inhibitory effects on enzymes involved in disease progression, showing promise in preclinical studies.
Used in Drug Development:
D-Cyclobutylalanine is used as a target for further research and drug development efforts due to its unique structure and biological activity. Its potential in the development of new drugs makes it an interesting compound for pharmaceutical research.

Check Digit Verification of cas no

The CAS Registry Mumber 174266-00-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,4,2,6 and 6 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 174266-00:
(8*1)+(7*7)+(6*4)+(5*2)+(4*6)+(3*6)+(2*0)+(1*0)=133
133 % 10 = 3
So 174266-00-3 is a valid CAS Registry Number.

174266-00-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (2R)-2-amino-3-cyclobutylpropanoic acid

1.2 Other means of identification

Product number -
Other names D-3-Cyclobutylalanine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:174266-00-3 SDS

174266-00-3Downstream Products

174266-00-3Relevant articles and documents

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

Johnson, Henry W.B.,Lowe, Eric,Anderl, Janet L.,Fan, Andrea,Muchamuel, Tony,Bowers, Simeon,Moebius, David C.,Kirk, Christopher,McMinn, Dustin L.

, p. 11127 - 11143 (2019/01/04)

Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown. We reveal here our design of peptide epoxyketone-based selective low molecular mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors. Utilizing these and our previously disclosed low molecular mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model. These and additional findings toward optimized solubility led the design and selection of KZR-616 disclosed here and presently in clinical trials for treatment of rheumatic disease.

Substituted Pyrazinone Amides

-

Page/Page column 17-18, (2010/08/07)

The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. The variables R1, R2

Anticoagulant peptidyl-arginine aldehyde derivatives

-

, (2008/06/13)

The invention relates to new peptidyl-arginine aldehyde compounds of formula (I) Q-D-Xaa-Pro-Arg-H??(I) wherein Q represents an acyl group of formula Q′—OCO, wherein Q′ represents an alkyl-group with 1-3 carbon atoms, D-Xaa represents a 3-cyclobutyl-D-ala

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 174266-00-3